Surveillance Among Healthcare Workers for SARS-Coronavirus-2 Infection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05175963

Enrollment

512

Registered

2022-01-04

Start date

2020-04-22

Completion date

2022-04-30

Last updated

2024-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, SARS-CoV2 Infection

Brief summary

This study aims to investigate the epidemiology of SARS-CoV-2 infection among: i) HCW who triage patients with suspected SARS-CoV-2 infection and provide care to COVID-19 patients; and ii) laboratory personnel who test clinical samples for SARS-CoV-2 infection. After the second wave of the pandemic enrolment will be widen to any person working at the study hospitals.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* HCWs of any staff category at the study hospitals.

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
To determine the prevalence of symptomatic and asymptomatic SARS-CoV-2 infections among HCW.	2020	To determine the prevalence of symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infections among HCW using a systematic sampling strategy, coupled with investigation when clinically indicated.

Secondary

Measure	Time frame	Description
To do sero-epidemiology assessment.	2022	To undertake serial sero-epidemiology studies on prevalence of SARS-CoV-2 antibodies among HCW.
To analyse immune responses to SARS-CoV-2 infection.	2022	To analyse immune responses (humoral and cell mediated) to SARS-CoV-2 infection.
To investigate the possibility of viral re-infection in this population during the study period.	2022	To investigate the possibility of viral re-infection during the different pandemic waves in this population during the study period.
To define the duration of viral shedding.	2020	To define the duration of shedding (using molecular based PCR methods) of SARS-CoV-2 in HCW who are identified to be infected with the virus.
To evaluate COVID-19 vaccine effectiveness (VE) amongst HCWs, against any PCR-confirmed SARS-CoV-2 infection.	2022	To evaluate COVID-19 vaccine effectiveness (VE) amongst HCWs, against any PCR-confirmed SARS-CoV-2 infection.
To measure humoral and cell mediated immune responses to COVID-19 vaccines stratified by previous SARS-CoV-2 infection.	2022	To measure humoral and cell mediated immune responses to COVID-19 vaccines stratified by previous SARS-CoV-2 infection.
To establish if common cold coronaviruses (CCCV) immunity confers protection against SARS-CoV-2 infection or disease severity	2022	To establish if common cold coronaviruses (CCCV) immunity confers protection against SARS-CoV-2 infection or disease severity by measuring antibodies to CCCV.

Countries

South Africa

Outcome results